biotech

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.

Vertex Pharmaceuticals faces cystic fibrosis revenue slowdown but eyes major growth catalysts with Casgevy gene-editing and povetacicept kidney disease therapies.

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

Iovance Biotherapeutics surged 34% in 2026 on strong melanoma drug sales, with analysts projecting 165% upside. Manufacturing challenges present significant execution risks.

Moderna beats revenue estimates with $389M vs. $227.97M consensus but shares fall 2.05% due to $2.22 per share litigation settlement charge.

Esperion Therapeutics agreed to be acquired by ARCHIMED for $1.1 billion, with shareholders receiving $3.16 per share plus up to $100 million in contingent payments—a 58% premium driving 57.5% premarket gains.

Seaport Therapeutics raised $255 million through IPO priced at $18/share, beginning Nasdaq trading Friday as ticker $SPTX, amid growing biotech IPO momentum.

Healthcare stocks $JNJ, $VRTX, and $UNH offer compelling long-term wealth-building opportunities through strong fundamentals, dividend history, and operational improvements.

Pfizer's 6.55% dividend yield offers attractive income but reflects patent cliff and pandemic revenue decline pressures. Strategic restructuring and Seagen acquisition signal transformation bid.

Kinikska Pharmaceuticals surged 24% after Q1 earnings beat. Arcalyst revenue jumped to $214M; net income more than doubled. Company raised full-year Arcalyst guidance to $930-945M.

Celcuity rises 4% after Citizens initiates 'market outperform' coverage with $150 price target, citing gedatolisib's breast cancer approval potential within two months and multi-indication opportunity.

Sionna director sells $2.5M in stock (2% of holdings) during 215% surge; $310M cash position supports pipeline through 2028.

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Kopp Family Office exits $3.5M Viridian stake as stock plummets 50% following disappointing Phase 3 data and Amgen's superior competing results.

Executive order fast-tracks psychedelics, spurring 40% surges in Compass Pathways and Atai Beckley, while cannabis operators like Curaleaf transition to stable income plays.

Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis, showing 90% tissue improvement and strong safety profile.

Legend Biotech surges 18% on bullish analyst upgrades and momentum from Eli Lilly's $7B CAR-T acquisition, with CD19/CD20 therapy driving investor enthusiasm.